Contact
searchSearch
HMP Global
Login
Quiz

AI Assistance for Immunohistochemistry Assessment of Breast Cancer

06/13/2025

Related Content

Paolo Tarantino, MD, PhD
Videos
Long-Term Results Support De-escalated Neoadjuvant Therapy in HER2-Positive Breast Cancer
07/22/2026
Paolo Tarantino, MD, PhD
Paolo Tarantino, MD, PhD, discusses 5-year results from the phase 2 DAPHNe trial showing that neoadjuvant paclitaxel, trastuzumab, and pertuzumab achieved excellent long-term outcomes with no distant recurrences among patients with...
Paolo Tarantino, MD, PhD, discusses 5-year results from the phase 2 DAPHNe trial showing that neoadjuvant paclitaxel, trastuzumab, and pertuzumab achieved excellent long-term outcomes with no distant recurrences among patients with...
Paolo Tarantino, MD, PhD,...
07/22/2026
Oncology
News
Trastuzumab Rezetecan Improves Progression-Free Survival in Previously Treated HER2-Positive Metastatic Breast Cancer
07/10/2026
Stephanie Holland
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
Interim results from the phase...
07/10/2026
Oncology
News
Anbenitamab Demonstrates Significant Neoadjuvant Benefit in HER2-Positive Breast Cancer
05/30/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved total pCR compared with standard neoadjuvant HER2-directed therapy in HER2-positive early or locally advanced breast cancer.
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved total pCR compared with standard neoadjuvant HER2-directed therapy in HER2-positive early or locally advanced breast cancer.
Results from a phase 3 trial...
05/30/2026
Oncology
Lajos Pusztai, MD, DPhil
Videos
T-DXd Improves Residual Cancer Burden in HER2-Positive Early Breast Cancer
05/19/2026
Lajos Pusztai, MD, DPhil
Lajos Pusztai, MD, DPhil, discusses post hoc analysis results from the of the phase 3 DESTINY-Breast11 trial assessing neoadjuvant T-DXd plus paclitaxel, trastuzumab, and pertuzumab in HER2-positive early breast cancer.
Lajos Pusztai, MD, DPhil, discusses post hoc analysis results from the of the phase 3 DESTINY-Breast11 trial assessing neoadjuvant T-DXd plus paclitaxel, trastuzumab, and pertuzumab in HER2-positive early breast cancer.
Lajos Pusztai, MD, DPhil,...
05/19/2026
Oncology

Recent News

News
Response-Guided PD-1 Therapy May Support Treatment De-Escalation in Advanced Cutaneous Squamous Cell Carcinoma
08/28/2026
Emily Estrada
A retrospective cohort study found that limited PD-1 exposure frequently produced durable disease control in patients with locally advanced or resectable cutaneous squamous cell carcinoma, with uncertain incremental benefit from treatment...
A retrospective cohort study found that limited PD-1 exposure frequently produced durable disease control in patients with locally advanced or resectable cutaneous squamous cell carcinoma, with uncertain incremental benefit from treatment...
A retrospective cohort study...
08/28/2026
Oncology
News
Ivonescimab Plus Chemotherapy Extends PFS After Tyrosine Kinase Inhibitor Progression in EGFR-Mutant Non-Small Cell Lung Cancer
08/28/2026
Stephanie Holland
Results from the phase 3 HARMONi trial showed that ivonescimab plus pemetrexed and carboplatin significantly improved progression-free survival compared with chemotherapy alone in patients with advanced EGFR-mutant non-small cell lung cancer...
Results from the phase 3 HARMONi trial showed that ivonescimab plus pemetrexed and carboplatin significantly improved progression-free survival compared with chemotherapy alone in patients with advanced EGFR-mutant non-small cell lung cancer...
Results from the phase 3 HARMONi...
08/28/2026
Oncology
News
Expert Consensus Establishes Imaging Recommendations for High-Risk Cutaneous Squamous Cell Carcinoma
08/28/2026
Emily Estrada
A multidisciplinary Delphi consensus established staging and surveillance imaging recommendations for localized cutaneous squamous cell carcinoma, supporting imaging for tumors with at least a 15% risk of metastasis and identifying specific...
A multidisciplinary Delphi consensus established staging and surveillance imaging recommendations for localized cutaneous squamous cell carcinoma, supporting imaging for tumors with at least a 15% risk of metastasis and identifying specific...
A multidisciplinary Delphi...
08/28/2026
Oncology
News
Twice-Daily Radiation Associated With Better Patient-Reported Outcomes in Limited-Stage Small Cell Lung Cancer
08/27/2026
Emily Estrada
A planned patient-reported outcomes analysis from NRG-LU005 found that adding atezolizumab to chemoradiation did not significantly reduce clinically meaningful decline at 15 months, while twice-daily radiation was consistently associated with...
A planned patient-reported outcomes analysis from NRG-LU005 found that adding atezolizumab to chemoradiation did not significantly reduce clinically meaningful decline at 15 months, while twice-daily radiation was consistently associated with...
A planned patient-reported...
08/27/2026
Oncology
News
Tarlatamab Reduces Symptom Burden and Treatment Side Effects in Extensive-Stage Small Cell Lung Cancer
08/27/2026
Emily Estrada
Patient-reported outcomes from the phase 3 DeLLphi-304 trial showed that tarlatamab delayed deterioration in key cancer-related symptoms and physical functioning while reducing treatment-related side-effect burden compared with standard...
Patient-reported outcomes from the phase 3 DeLLphi-304 trial showed that tarlatamab delayed deterioration in key cancer-related symptoms and physical functioning while reducing treatment-related side-effect burden compared with standard...
Patient-reported outcomes from...
08/27/2026
Oncology
News
Five-Year KEYNOTE-942 Results Show Durable Benefit With Intismeran Plus Pembrolizumab in Resected Melanoma
08/27/2026
Stephanie Holland
Five-year results from the phase 2b KEYNOTE-942 trial showed that intismeran plus pembrolizumab maintained durable improvements in recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Five-year results from the phase 2b KEYNOTE-942 trial showed that intismeran plus pembrolizumab maintained durable improvements in recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Five-year results from the phase...
08/27/2026
Oncology
FDA Approval
FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma
08/26/2026
Emily Estrada
The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least 1 prior systemic therapy or are not candidates for multiagent systemic therapy after phase 3 RASolute 302 data showed significant...
The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least 1 prior systemic therapy or are not candidates for multiagent systemic therapy after phase 3 RASolute 302 data showed significant...
The FDA approved daraxonrasib...
08/26/2026
Oncology
News
Biomarker-Driven GUIDANCE Trial Targets HRD-Positive Small Cell Lung Cancer With Olaparib Plus Durvalumab
08/25/2026
Stephanie Holland
The phase 2 GUIDANCE trial is evaluating maintenance olaparib plus durvalumab in homologous recombination deficiency-positive advanced or metastatic small cell lung cancer after first-line chemoimmunotherapy, testing whether prospective...
The phase 2 GUIDANCE trial is evaluating maintenance olaparib plus durvalumab in homologous recombination deficiency-positive advanced or metastatic small cell lung cancer after first-line chemoimmunotherapy, testing whether prospective...
The phase 2 GUIDANCE trial is...
08/25/2026
Oncology
FDA Approval
FDA Approves Zanidatamab-Based Regimens for First-Line HER2-Positive Advanced Gastroesophageal Adenocarcinoma
08/25/2026
Stephanie Holland
The FDA approved zanidatamab plus chemotherapy, with or without tislelizumab, for first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma after phase 3 HERIZON-GEA-01 data showed significant...
The FDA approved zanidatamab plus chemotherapy, with or without tislelizumab, for first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma after phase 3 HERIZON-GEA-01 data showed significant...
The FDA approved zanidatamab...
08/25/2026
Oncology
News
ESMO Recommends Daraxonrasib After Chemotherapy for RAS G12–Mutant Metastatic Pancreatic Cancer
08/19/2026
Stephanie Holland
ESMO guidelines recommend daraxonrasib as a second-line treatment after chemotherapy for patients with RAS G12–mutant metastatic pancreatic cancer and ECOG performance status 0 to 1, based on phase 3 improvements in survival, response, and...
ESMO guidelines recommend daraxonrasib as a second-line treatment after chemotherapy for patients with RAS G12–mutant metastatic pancreatic cancer and ECOG performance status 0 to 1, based on phase 3 improvements in survival, response, and...
ESMO guidelines recommend...
08/19/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use